HALOZYME THERAPEUTICS INC holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 3,674,302 | $234,457,211 | 5.12% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 15, 2025 |
| June 30, 2025 | 3,397,697 | $176,748,198 | 3.76% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 12, 2025 |
| Sept. 30, 2025 | 2,733,844 | $200,500,119 | 3.79% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 12, 2025 |
| Dec. 31, 2025 | 2,399,188 | $161,465,352 | 3.01% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 12, 2026 |
| March 31, 2026 | 2,323,077 | $150,140,467 | 2.91% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 14, 2026 |
| June 30, 2026 | 2,396,101 | $187,542,825 | 3.24% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 13, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.